Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TriSalus Life Sciences, Inc. - Common Stock (NQ:TLSI)

3.585 -0.365 (-9.24%)
Streaming Delayed Price Updated: 2:00 PM EDT, Aug 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TriSalus Life Sciences, Inc. - Common Stock

< Previous 1 2 3 Next >
TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
From TriSalus Life Sciences
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board
From TriSalus Life Sciences
Via Business Wire
TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System
From TriSalus Life Sciences
Via Business Wire
TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q2 2024
TLSI stock results show that TriSalus Life Sciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
TriSalus Reports Q2 2024 Financial Results and Business Update
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting
From TriSalus Life Sciences
Via Business Wire
Crude Oil Rises 1%; Verastem Shares Slide
 
Via Benzinga
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Nasdaq Gains 1%; Intuit Shares Plunge
 
Via Benzinga
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
From TriSalus Life Sciences
Via Business Wire
TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q1 2024
TLSI stock results show that TriSalus Life Sciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
TriSalus Reports Q1 2024 Financial Results and Business Update
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives
From TriSalus Life Sciences
Via Business Wire
TLSI Stock Earnings: TriSalus Life Sciences Misses EPS, Beats Revenue for Q4 2023
TLSI stock results show that TriSalus Life Sciences missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting
From TriSalus Life Sciences
Via Business Wire
Earnings Scheduled For April 1, 2024
Companies Reporting Before The Bell • Mach Natural Resources (NYSE:MNR) is projected to report quarterly earnings at $0.92 per share on revenue of $213.43 million. 
Via Benzinga
TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors
From TriSalus Life Sciences
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update
From TriSalus Life Sciences Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback